Pulmonx to Present at Upcoming September Investor Conferences

Pulmonx Corporation (Nasdaq: LUNG) announced its participation in two virtual investor conferences.

Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) announced its participation in two virtual investor conferences. Management will engage in fireside chats at the 2021 Virtual Wells Fargo Healthcare Conference on September 9, 2021, at 7:00 AM PT and the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 1:15 PM PT. Interested parties can access live and archived webcasts on the Pulmonx website. Pulmonx is known for its minimally invasive treatments for severe lung diseases, including the Zephyr Endobronchial Valve, which has received FDA approval and is available in over 25 countries.

Argus Session date unavailable

+3.83% session move Open Argus

Details

News Market Reaction – LUNG

The recorded move for LUNG in the trading session of this news was +3.83%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) today announced the company will be participating in fireside chats at two upcoming virtual investor conferences. Pulmonx management is scheduled to participate in the 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021 at 7:00am PT / 10:00am ET and the Morgan Stanley 19^th Annual Global Healthcare Conference on Monday, September 13, 2021 at 1:15pm PT / 4:15pm ET.

Interested parties may access live and archived webcasts of the fireside chats on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx
Pulmonx Corporation (NASDAQ: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr^® Endobronchial Valve, Chartis^® Pulmonary Assessment System and StratX^® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who, despite medical management, are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 80,000 valves used to treat more than 20,000 patients. For more information on the Zephyr Valves, please visit www.MyLungsMyLife.com. For more information on the company, please visit www.Pulmonx.com.

Pulmonx^®, Chartis^®, StratX^®, and Zephyr^® are registered trademarks of Pulmonx Corporation.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com

 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Pulmonx participating in the Virtual Wells Fargo Healthcare Conference?

Pulmonx will participate in the Virtual Wells Fargo Healthcare Conference on September 9, 2021, at 7:00 AM PT.

What is the date and time for the Morgan Stanley Global Healthcare Conference for Pulmonx?

Pulmonx is scheduled for the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 1:15 PM PT.

How can I access the webcasts of Pulmonx's fireside chats?

Live and archived webcasts of Pulmonx's fireside chats can be accessed in the 'Investors' section of their website.

What products does Pulmonx offer for lung disease treatment?

Pulmonx offers products like the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, and StratX Lung Analysis Platform for treating severe emphysema/COPD.

Has Pulmonx received FDA approval for any of its devices?

Yes, Pulmonx received FDA pre-market approval for the Zephyr Valve, which is designated as a 'breakthrough device'.